Editorial · 2023 · Open access

Editorial: PROTACs: Targeted therapies for cancer treatment

Sobia Tabassum

Frontiers in Cell and Developmental Biology, 11, 1102721 · Published 3 February 2023 · DOI 10.3389/fcell.2023.1102721

Open PDFView at the publisherCite this paper

In brief

“Editorial: PROTACs: Targeted therapies for cancer treatment” is an 2023 editorial by Sobia Tabassum, published in Frontiers in Cell and Developmental Biology. OpenAlex counts 1 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Cell and Developmental Biology.

Citations
1
Most cited in
2025 (1)
References
1
Authors
1

Abstract

Editorial for the Research Topic: PROTACs: Targeted Therapies for Cancer TreatmentSobia TabassumDepartment of Biological Sciences, International Islamic University, Islamabad, PakistanCancer is one of the leading cause of morbidity and mortality worldwide. The development of chemotherapeutic drug resistance, which causes the disease to reoccur, has decreased the effectiveness of cancer treatments. Proteolysis-targeting chimaera (PROTACs) are protein targeting chimeric molecules that have the capacity to bind disease-causing protein of interest with a high degree of specificity and then lyse it. PROTACs are specialized, adaptable, and biologically active. They have tremendous advantages over other types of inhibitors which are not able to give protection against the drug resistivity issue in cancer as they have the ability to trigger selective intracellular proteolysis, which can be utilized to specifically target and destroy tumor-promoting proteins inside of cells. To enhance their therapeutic outcomes, new understandings of the molecular mechanisms of PROTAC-mediated degradation are required. Aim and Objectives:The current research topic aims to explore the most recent developments in the creation and use of PROTACS-based treatments for cancer. We invite research articles, review articles, and viewpoints that address to the following issues, but are not restricted to them.• Molecular underpinnings of PROTAC-mediated protein degradation• Modulation of the ubiquitination system for cancer treatment• Innovative designing and development of PROTACS-based therapeutics• Comparison of PROTACs with non-targeted and targeted therapiesThis research topic brings together several scientific contributions that highlight some extremely exciting findings. The published articles on this topic have attracted significant interest from both academia and industry.Burke et al. (2022) submitted a comprehensive review on this subject in order to address cancer drug resistance, which is a significant obstacle to the successful treatment of malignancies going forward. Recent developments in this field of study show that PROTACs can successfully destroytargets that confer cancer resistance to therapies, building the foundation for next-generation therapies and that provide additional clinical benefit to patients.The authors provided an overview of the current use of PROTACs to treat solid tumors and included recommendations for overcoming their clinical development roadblocks. Among designing and development constraints, improvements in bioavailability and safety brought about by an improved delivery route seem to be relevant. In light of this, Juan et al. (2021) have proposed methods to enhance their therapeutic efficacy and the development of fine-tuned nanoparticles based delivery systems to increase the bioactivity of PROTACs.Significant developments in newly developed degrader technologies were also reported in this area (Luo et al. 2022). The emphasis of the authors has been on the molecular design of PROTACs using various methodologies, which provides…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Tabassum, S. (2023). Editorial: PROTACs: Targeted therapies for cancer treatment. Frontiers in Cell and Developmental Biology, 11, 1102721. https://doi.org/10.3389/fcell.2023.1102721

MLA 9

Tabassum, Sobia. “Editorial: PROTACs: Targeted therapies for cancer treatment.” Frontiers in Cell and Developmental Biology, vol. 11, 2023, p. 1102721. https://doi.org/10.3389/fcell.2023.1102721.

Chicago

Tabassum, Sobia. 2023. “Editorial: PROTACs: Targeted therapies for cancer treatment.” Frontiers in Cell and Developmental Biology 11: 1102721. https://doi.org/10.3389/fcell.2023.1102721.

Harvard

Tabassum, S. (2023) ‘Editorial: PROTACs: Targeted therapies for cancer treatment’, Frontiers in Cell and Developmental Biology, 11, p. 1102721. doi:10.3389/fcell.2023.1102721.

IEEE

S. Tabassum, “Editorial: PROTACs: Targeted therapies for cancer treatment,” Frontiers in Cell and Developmental Biology, vol. 11, p. 1102721, 2023, doi: 10.3389/fcell.2023.1102721.

BibTeX

@article{tabassum2023editorial,
  title     = {{Editorial: PROTACs: Targeted therapies for cancer treatment}},
  author    = {Tabassum, Sobia},
  journal   = {Frontiers in Cell and Developmental Biology},
  year      = {2023},
  volume    = {11},
  pages     = {1102721},
  doi       = {10.3389/fcell.2023.1102721},
  url       = {https://doi.org/10.3389/fcell.2023.1102721}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • chemoresistance
  • ubiquitination
  • targeted cancer therapy
  • solid tumors
  • nanoparticle drug delivery

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Tabassum, S. (2023). Editorial: PROTACs: Targeted therapies for cancer treatment. Frontiers in Cell and Developmental Biology, 11, 1102721. https://doi.org/10.3389/fcell.2023.1102721

How many times has this paper been cited?

1 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Cell and Developmental Biology: sign in and open the PDF from this page.

Who wrote this paper?

Sobia Tabassum.

What is the DOI of this paper?

10.3389/fcell.2023.1102721, permanently at https://doi.org/10.3389/fcell.2023.1102721. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.